---
title: "These Analysts Revise Their Forecasts On GH Research After Q1 Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286585655.md"
description: "GH Research (NASDAQ:GHRS) reported a Q1 loss of 31 cents per share, exceeding expectations of 28 cents. Following this, analysts revised their price targets: Citizens lowered from $42 to $39, while Cantor Fitzgerald raised from $25 to $35. The stock fell 3.4% to $21.46. CEO Dr. Velichka Valcheva noted progress in the GH001 program."
datetime: "2026-05-15T14:58:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286585655.md)
  - [en](https://longbridge.com/en/news/286585655.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286585655.md)
---

# These Analysts Revise Their Forecasts On GH Research After Q1 Results

**GH Research PLC** (NASDAQ:GHRS) reported a wider-than-expected loss for the first quarter on Thursday.

The company posted quarterly losses of 31 cents per share which missed the analyst consensus estimate of losses of 28 cents per share.

“The first quarter of 2026 marks progress as planned toward our global GH001 Phase 3 pivotal program,” said Dr. Velichka Valcheva, Chief Executive Officer.

GH Research shares fell 3.4% to trade at $21.46 on Friday.

These analysts made changes to their price targets on GH Research following earnings announcement.

-   Citizens analyst Jason N. Butler maintained GH Research with a Market Outperform and lowered the price target from $42 to $39.
-   Cantor Fitzgerald analyst Charles Duncan maintained the stock with an Overweight rating and raised the price target from $25 to $35.

**Considering buying GHRS stock? Here’s what analysts think:**

_Photo via Shutterstock_

### Related Stocks

- [GHRS.US](https://longbridge.com/en/quote/GHRS.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [CFG.US](https://longbridge.com/en/quote/CFG.US.md)
- [CFG-I.US](https://longbridge.com/en/quote/CFG-I.US.md)
- [CFG-E.US](https://longbridge.com/en/quote/CFG-E.US.md)
- [CFG-H.US](https://longbridge.com/en/quote/CFG-H.US.md)

## Related News & Research

- [Ireland's GH Research Q1 net loss widens on higher expenses](https://longbridge.com/en/news/286406432.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)